まとめ
国立心臓,肺,血液研究所 (NHLBI) は,心血管および肺疾患の生物医学研究と臨床試験を推進しています. 彼らの研究は,心臓発作,高血圧,脳卒中による死亡率を低減する進歩につながりました.
科学分野:
- バイオメディカル研究
- 心血管疾患や肺疾患について
- クリニック・トライアル 臨床試験
背景:
- 1948年に国立心臓研究所として設立されました.
- 心臓,肺,血液,血管疾患に関する国家研究プログラムを主導した.
- 研究成果を検証するための複雑な臨床試験にますます関与しています.
研究 の 目的:
- 新しい基本的な情報を取得し,評価する.
- 研究成果を応用して,病気の予防,発見,治療を改善する.
- ヘルスケアアプリケーションのためのデモと教育活動をスポンサーにします.
主な方法:
- 複雑な臨床試験を実施する.
- 新しい生物医学情報の取得と評価.
- デモと教育活動のスポンサー.
主要な成果:
- 心肺器,ペースメーカーなどの新機器の開発.
- 診断手順,手術装置,治療法の改善.
- 心臓発作,高血圧,脳卒中による死亡率の大幅な減少.
結論:
- NHLBIの包括的なアプローチは,病気の予防と治療を強化します.
- テクノロジーと医療の進歩により,心血管疾患および脳血管疾患による死亡率が大幅に低下しました.
- 継続的な研究と発見の応用は,公衆衛生にとって極めて重要です.
さらに関連する動画
13:07Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
06:04Pulse-Wave Velocity, Flow-Mediated Dilation, and Carotid Intima-Media Thickness to Assess Cardiovascular Risk in Population with Metabolic Syndrome
Published on: September 27, 2024
関連する概念動画
Preventive Healthcare Services
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Assessment of the Cardiovascular System I: Subjective Data
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
